GlassScriptPhysician profile
Dawn H Degrasse
NPI 1255756342
$8,297.23
in general payments reported to CMS, 2019-2025
33 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,181 · 2022: $2,054 · 2023: $1,892 · 2024: $1,764 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.92 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,033.99 | 2021-2025 | |
| Janssen Biotech, INC. | $1,026.07 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $996.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $796.95 | 2021-2025 | Saphnelo, Airsupra, Farxiga |
| Amgen INC. | $780.76 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $704.52 | 2021-2025 | Benlysta, Trelegy Ellipta |
| Lilly USA, LLC | $694.96 | 2021-2025 | Jardiance, Taltz, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.38 | 2021-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $339.33 | 2021-2025 | Acthar |
| Ucb, INC. | $337.02 | 2021-2024 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $212.05 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $111.68 | 2021-2024 | Eliquis, Camzyos |
| Genentech USA, INC. | $86.03 | 2023-2024 | Actemra |
| Janssen Pharmaceuticals, INC | $73.01 | 2021 | |
| Novo Nordisk INC | $66.61 | 2021-2025 | Rybelsus, Ozempic |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.20 | 2021-2022 | |
| Exact Sciences Corporation | $61.53 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $55.54 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.33 | 2021-2022 | |
| Sandoz INC. | $44.77 | 2024 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $44.59 | 2024 | |
| Nestle Healthcare Nutrition INC. | $38.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.25 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $35.24 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $35.20 | 2023 | Zilretta |
| Octapharma USA, INC. | $33.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.06 | 2021 | |
| Hikma Pharmaceuticals USA | $20.44 | 2023 | Mitigare |
| Biohaven Pharmaceutical Holding Company LTD. | $20.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.97 | 2024 | Voquezna |
| Eisai INC. | $15.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Degrasse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.